Compare LQDA & STNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | STNE |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 2020 | 2018 |
| Metric | LQDA | STNE |
|---|---|---|
| Price | $42.61 | $10.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $41.00 | $19.07 |
| AVG Volume (30 Days) | 930.9K | ★ 5.5M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $15.07 |
| Revenue Next Year | $57.13 | $6.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $10.74 |
| 52 Week High | $46.67 | $19.95 |
| Indicator | LQDA | STNE |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 30.42 |
| Support Level | $35.00 | N/A |
| Resistance Level | $46.67 | $15.80 |
| Average True Range (ATR) | 1.65 | 0.45 |
| MACD | 0.46 | -0.18 |
| Stochastic Oscillator | 92.74 | 1.70 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.